<DOC>
	<DOCNO>NCT01829919</DOCNO>
	<brief_summary>The purpose study ass pharmacokinetics ( absorption , breakdown elimination body ) , safety tolerability Brisdelle ( paroxetine mesylate ) Capsules 7.5 mg give single dose multiple dos .</brief_summary>
	<brief_title>Pharmacokinetic Evaluation Brisdelle™ ( Formerly Known Mesafem ) Following Single &amp; Repeat Oral Administration Healthy Postmenopausal Women</brief_title>
	<detailed_description>This study research design treat medical condition .</detailed_description>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>Subjects healthy postmenopausal , nonsmoking woman race ≥40 year age screening . Subjects recent history presence glaucoma , migraine , cardiovascular , hepatobiliary , renal , gastrointestinal , neurologic , psychiatric , dermatologic , pulmonary , cerebrovascular , endocrine , hematologic , thromboembolic , immunologic disease disorder require physician care ; subject exist medical condition might interfere absorption , distribution , metabolism , excretion study medication ; history selfinjurious behavior ; history clinical diagnosis depression ; treatment depression ; history clinical diagnosis borderline personality disorder ; presence follow psychiatric disorder within timeframes specify : Major Depressive DisorderLifetime ; DysthymiaPast 2 Years ; Bipolar DisorderLifetime ; Panic DisorderLifetime ; AgoraphobiaPast Month ; Social PhobiaPast Month ; Obsessive Compulsive DisorderPast Month ; Generalized AnxietyLifetime ; Psychotic DisordersLifetime ; Anorexia NervosaPast 10 Years ; BulimiaPast 10 Years ; Suicidality/Suicide IdeationLifetime ; Post Traumatic Stress DisorderLifetime . Subjects history seizure ; sit blood pressure ( BP ) &lt; 90/50 &gt; 150/90 mmHg ; sit heart rate ( HR ) &lt; 45 &gt; 90 beats/min ; clinical laboratory test result outside normal range laboratory conduct test ; positive urine pregnancy test Screening Day 0 ; subject history sensitivity active and/or inactive ingredient Brisdelle ( paroxetine mesylate ) Capsules 7.5 mg ; subject history significant allergy ; subject present past history narcotic addiction , drug abuse , alcoholism ; subject smoke use tobacco last 6 month ; subject donate one pint blood within 30 day prior treatment administration ; subject symptoms significant acute illness screen visit ; subject use investigational drug within 30 day prior treatment administration ; subject take substance know Cytochrome P450 2D6 ( CYP2D6 ) inhibitor within 14 day study start throughout entire study ; subject use prescription medication within 14 day screen visit ; subject use St John 's Wort within 14 day screen visit ; subject use counter preparation include herbal nutritional supplement multivitamin within 10 day prior receive first study treatment ; subject consume food beverage contain caffeine/xanthine alcohol ; subject positive screen hepatitis B surface antigen ( HBsAg ) hepatitis C antibody ; subject positive screen Human Immunodeficiency Virus ( HIV ) antibody ; subject positive urine drug screen ; subject clinically significant illness within 90 day prior receive first dose study medication .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Menopause</keyword>
	<keyword>Hot flash</keyword>
	<keyword>Vasomotor symptom</keyword>
	<keyword>Climacteric symptom</keyword>
	<keyword>perimenopause</keyword>
	<keyword>Mesafem</keyword>
	<keyword>Brisdelle</keyword>
	<keyword>Low-Dose Mesylate salt Paroxetine ( LDMP )</keyword>
</DOC>